In recent years therapeutic options for ovarian cancer have increased. Prior to 2016, the only targeted therapy approved for the indication was AstraZeneca’s Lynparza. However, the treatment…
The wet age-related macular degeneration (AMD) market in the United States is unique given that the key approved therapies—Roche / Genentech’s Lucentis, Regeneron’s Eylea, and Novartis’s…
Although several effective anti-inflammatory agents and bronchodilators are available to control disease in mild-to-moderate asthmatics, great unmet need exists in the treatment of severe disease…
The type 2 diabetes market has become increasingly crowded, with therapies competing over preferential formulary placement as well as patient share. Using primary research from U.S…
A patient with major depressive disorder (MDD) who does not achieve adequate response to more than two different trials of antidepressant drugs is then usually considered as having treatment-…
Chronic kidney disease (CKD) is a general term for a set of heterogeneous disorders that negatively affect the function and structure of the kidney. Because of the role of the kidney in many of the…
The type 2 diabetes therapy market will rapidly expand over our 2016-2026 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in…
Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages and AD prevalence grows, the need for drugs to treat…
Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…
Obesity is arguably the most pressing public health issue in the United States. Prevalence of obesity is extremely high, and its chronic progression is associated with type 2 diabetes and adverse…
Systemic lupus erythematosus (SLE) is a complex disease characterized by distinct manifestations. Currently, most treatments available to treat SLE are used off-label. The approval of Benlysta in…
Recent launches of Celltrion’s Truxima (rituximab) and Sandoz’s Rixathon (rituximab) have expanded the biosimilar sector of the European oncology market. In the United States, only a single…
The market for Alzheimer’s disease (AD) pharmacotherapies represents an enormous commercial opportunity driven by considerable unmet need and looming societal burden. The AD population is…
There is increased industry focus on the behavioral symptoms of Alzheimer’s disease (AD), including agitation—and with good reason. Agitation affects the majority of diagnosed AD patients,…
The primary goals of pharmacotherapy in UC are to induce remission during acute flares and to maintain long-term corticosteroid-free remission, once remission is achieved. UC treatment regimens are…
